Herbal Medicines in the Treatment of Psychiatric and Neurological Disorders

  • Shahin Akhondzadeh
Chapter

Keywords

Herbal Medicine Generalize Anxiety Disorder Hypericum Perforatum Ginkgo Biloba Extract Ginkgo Biloba Extract 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abdullaev, F. I. (2002). Cancer chemopreventive and tumoricidal properties of saffron (Crocus sativus L.). Experimental Biology and Medicine, 227, 20–25.PubMedGoogle Scholar
  2. Abe, K., & Saito, H. (2000). Effects of saffron and its constituent crocin on learning behavior and long-term potentiation. Phytotherapy Research, 14, 149–152.PubMedCrossRefGoogle Scholar
  3. Akhondzadeh, S., Naghavi, H. R., Vazirian, M., Shayeganpour, A., Rashidi, H., & Khani, M. (2001a). Passionflower in the treatment of generalized anxiety: A double-blind and randomized trial with oxazepam. Journal of Clinical Pharmacy and Therapeutics, 26, 363–367.CrossRefGoogle Scholar
  4. Akhondzadeh, S., Kashani, L., Mobaseri, M., Hosseini, S. H., Nikzad, S., & Khani, M. (2001b). Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial. Journal of Clinical Pharmacy and Therapeutics, 26, 369–373.CrossRefGoogle Scholar
  5. Akhondzadeh, S., & Noroozian, M. (2002). Alzheimer’s disease: pathophysiology and Pharmacotherapy. Idrugs, 4, 1167–1172.Google Scholar
  6. Akhondzadeh, S., Noroozian, M., Mohammadi, M., & Ohadinia, S. (2003a). Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomised, placebo controlled trial. Journal of Neurology, Neurosurgery and Psychiatry, 74, 863–866.CrossRefGoogle Scholar
  7. Akhondzadeh, S., Noroozian, M., Mohammadi, M., & Ohadinia, S. (2003b). Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomized and placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics, 28, 53–59.CrossRefGoogle Scholar
  8. Akhondzadeh, S., Kashani, L., Fotouhi, A., & Jarvandi, S. (2003). Comparison of Lavandula angostofolia Mill. tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized pilot study. Progress in Neuropsychopharmacology and Biological Psychiatry, 27, 123–127.CrossRefGoogle Scholar
  9. Akhondzadeh, S., Fallah Pour, H., Afkham, K., Jamshidi, A. H., & Khalighi-Cigarodi, F. (2004). Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. BMC Complementary and Alternative Medicine, 4, 12.PubMedCrossRefGoogle Scholar
  10. Akhondzadeh, S., Tamacebi-pour, N., Noorbala, A. A., Amini, H., Fallah Pour, H., Jamshidi, A. H., & Khani, M. (2005a). Crocus sativus L. in the treatment of mild to moderate depression: A double-blind, randomized and placebo controlled trial. Phytotherapy Research, 19, 25–29.CrossRefGoogle Scholar
  11. Akhondzadeh, S., Mohammadi, M. R., & Momeni F. (2005b). Passiflora incarnata in treatment of attention-deficit hyperactivity disorder in children and adolescents. Therapy, 2, 609–614.CrossRefGoogle Scholar
  12. Astin, J. A. (1998). Why patients use alternative medicine: results of a national study. Journal of the American Medical Association, 279, 1548–1553.PubMedCrossRefGoogle Scholar
  13. Balderer, G., & Borbely, A. A. (1985). Effect of valerian on human sleep. Psychopharmacology, 87, 406–409.PubMedCrossRefGoogle Scholar
  14. Becker, B., Bock, B., & Carmona-Barros, R. (2003). St John’s Wort oral spray reduces withdrawal symptoms during quitting smoking. In: Society for Research on Nicotine and Tobacco 9th Annual Meeting, New Orleans, Louisiana.Google Scholar
  15. Brue, A. W., & Oakland, T. D. (2002). Alternative treatments for attention deficit hyperactivity disorders: Does evidence support their use. Alternative Therapy Medicine, 8, 68–74.Google Scholar
  16. Bullock, R. (2001). Drug treatment in dementia. Current Opinion in Psychiatry, 14, 349–353.CrossRefGoogle Scholar
  17. Bullock, R. (2002). New drugs for Alzheimer’s disease and other dementias. British Journal of Psychiatry, 180, 135–139.PubMedCrossRefGoogle Scholar
  18. Connor, K. M., & Davidson, J. R. (2002). A placebo-controlled study of Kava kava in generalized anxiety disorder. International Clinical Psychopharmacology, 17, 185–188.PubMedCrossRefGoogle Scholar
  19. Catania, M. A., Firenzuoli, F., & Crupi, A. (2003). Hypericum perforatum attenuates nicotine withdrawal signs in mice. Psychopharmacology, 169, 186–189.PubMedCrossRefGoogle Scholar
  20. Dean, A. J. (2005). Natural and complementary therapies for substance use disorders. Current Opinion in Psychiatry, 18, 271–276.PubMedCrossRefGoogle Scholar
  21. Delaveau, P., Guillemain, J., Narcisse, G., & Rousseau, A. (1989). Neurodepressive properties of essential oil of lavender. Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, 183, 342–348.PubMedGoogle Scholar
  22. De Feudis, F. V. (1991). Gingko biloba extract (EGb761): pharmacological activities and clinical applications. Paris: Elsevier.Google Scholar
  23. Donath, F., Quispe, S., & Diefenbach, K. (2000). Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry, 33, 47–53.PubMedCrossRefGoogle Scholar
  24. Evans, D. A., Funkenstein, H. H., & Albert, M. S. (1989). Prevalence of Alzheimer’s disease in a community population of older persons: higher than previously reported. Journal of the American Medical Association, 262, 2551–2556.PubMedCrossRefGoogle Scholar
  25. Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999). The cholinergic hypothesis of Alzheimer’s disease: a review of progress. Journal of Neurology, Neurosurgery and Psychiatry, 54, 137–147.Google Scholar
  26. Gaster, B., & Holroyd, J. (2000). St. John’s wort for depression: A systematic review. Archive of Internal of Medicine, 160, 152–156.CrossRefGoogle Scholar
  27. Geldmacher, D. S., & Whitehouse, P. J. (1997). Differential diagnosis of Alzheimer’s disease. Neurology, 48(Suppl. 6), S2–S9.PubMedGoogle Scholar
  28. Gelenberg, A. J. (2000). St. John’s Wort update. Biological Therapies in Psychiatry, 23, 22–24.Google Scholar
  29. Hansgen, K. D., Vesper, J., & Ploch, M. (1994). Multicenter double-blind study examining the antidepressant effectiveness of the hypericum extract L160. Journal of Geriatric Psychiatry and Neurology, 7, S15–S18.PubMedCrossRefGoogle Scholar
  30. Hosseinzadeh, H., & Younesi, H. (2002). Petal and stigma extracts of Crocus sativus L. have antinociceptive and anti-inflammatory effects in mice. BMC Pharmacology, 2, 7.PubMedCrossRefGoogle Scholar
  31. Kanowski, S., & Hoerr, R. (1997). Proof of the efficacy of the gingko biloba special extract egb761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type of multi-infarct dementia. Phytomedicine, 4, 215–222.Google Scholar
  32. Kennedy, D. O., Scholey, A. B., Tildesley, N. T. J., Perry, E. K., & Wesnes, K. A. (2002). Modulation of mood and cognitive performance following acte adminstration of Melissa officinalis (lemon balm). Pharmacology and Biochemistry and Behavior, 72, 953–964.CrossRefGoogle Scholar
  33. Kim, H. L., Streltzer, J., & Goebert, D. (1999). St. John’s wort for depression: A meta-analysis of well-defined clinical trials. Journal of Nervous and Mental Disease, 187, 532–539.PubMedCrossRefGoogle Scholar
  34. Kleijnen, J. (1992). Gingko biloba. Lancet, 340, 1136–1139PubMedCrossRefGoogle Scholar
  35. Le Bars, P. L., Katz, M. M., Berman, N., Itil, T. M., Freedman, A. M., & Schatzberg, A. F. (1997). A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. Journal of the American Medical Association, 278, 1327–1332.PubMedCrossRefGoogle Scholar
  36. Le Bars, P. L., Kieser, M., & Itil, K. Z. (2000). A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia. Dementia, Geriatric and Cognition Disorder, 11, 230–237.CrossRefGoogle Scholar
  37. Lehmann, E., Kinzler, E., & Friedmann, J. (1996). Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension, excitedness of non-mental origin: A double-blind, placebo-controlled study of four weeks treatment. Phytomedicine, 3, 113–119.Google Scholar
  38. Lieberman, S. (1998). Nutriceutical review of St. John’s wort (hypericum perforatum) for the treatment of depression. Journal of Women’s Health, 7, 177–182.PubMedCrossRefGoogle Scholar
  39. Linde, K., Ramirez, G., & Mulrow, C. D. (1996). St. John’s wort for depression: An overview and meta-analysis of randomised clinical trials. BMJ, 313, 253–258.PubMedGoogle Scholar
  40. Lindenberg, D., & Pitule-Schodel, H. (1990). Kava in comparison with oxazepam and anxiety disorders: A double- blind study of clinical effectiveness. Fortschr Medicine, 108, 49–54.Google Scholar
  41. Livingston, G., & Katona, C. (2000). How useful are cholinesterase inhibitor in the treatment of Alzheimer’s disease? A number needed to treat analysis. International Journal of Geriatric Psychiatry, 15, 203–207.PubMedCrossRefGoogle Scholar
  42. Medical Economics. (2000). PDR (Physicians’ Desk Reference) for Herbal Medicines (2nd edn). Montvale, NJ: Medical Economics Company.Google Scholar
  43. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of AD: Report of NINCDS-ADRDA work group under the auspices of department of health and human services task force on AD. Neurology, 34, 939–944.PubMedGoogle Scholar
  44. Noorbala, A. A., Akhondzadeh, S., Tamacebi-pour, N., & Jamshidi, A. H. (2005). Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: A double-blind, randomized pilot trial. Ethnopharmacology, 97, 281–284.PubMedCrossRefGoogle Scholar
  45. Perry, E. K., Pikering, A. T., Wang, W. W., Houghton, P. J., & Perry, N. S. (1998). Medicinal plants and Alzheimer’s disease: integrating ethnobotanical and contemporary scientific evidence. Journal of Alternative and Complementary Medicine, 4, 419–428.Google Scholar
  46. Perry, E. K., Pikering, A. T., Wang, W. W., Houghton, P. J., & Perry, N. S. (1999). Medicinal plants and Alzheimer’s disease: from etnobotany to phytotherapy. Journal of Pharmacology, 51, 527–534.CrossRefGoogle Scholar
  47. Pittler, M. H., & Ernst, E. (2000). Efficacy of kava extract for treating anxiety: Systematic review and meta-analysis. Journal of Clinical Psychopharmacology, 20, 84–89.PubMedCrossRefGoogle Scholar
  48. Richelson, E. (1994). Pharmacology of antidepressants-characteristic of the ideal drug. Mayo Clinic Proceeding, 69, 1069–1081.Google Scholar
  49. Rios, J. L., Recio, M. C., Giner, R. M., & Manez, S. (1996). An update review of saffron and its active constituents. Phytotherapy Research, 10, 189–193.CrossRefGoogle Scholar
  50. Schelosky, L., Raffauf, C., & Jendroska, K. (1995). Kava and dopamine antagonism [letter]. Journal of Neurology, Neurosurgery and Psychiatry, 58, 639–640.Google Scholar
  51. Schulz, V. (2003). Gingko extract or cholinesterase inhibitors in patients with dementia: what clinical trials and guidelines fail to consider. Phytomedicine, 14(Suppl. 10), 74–79.CrossRefGoogle Scholar
  52. Schulz, V., Hansel R., & Tyler, V. E. (1998). Rational phytotherapy: a physicians’ guide to herbal medicine (3rd ed.). Berlin, Germany: Springer-Verlag.Google Scholar
  53. Sensenig, J., Marrongelle, J., Johnson, M., & Staverosky, T. (2001). Treatment of migraine with targated nutrition focused on improved assimilation and eliminiation. Alternative Medicine Review, 6, 488–494.PubMedGoogle Scholar
  54. Sproule, B.A., Busto, U.E., & Buckle, C. (1999). The use of non-prescription sleep products in the elderly. International Journal of Geriatric Psychiatry 14, 851–857.PubMedCrossRefGoogle Scholar
  55. Szatmari, S. Z., & Whitehouse, P. J. (2003). Vinpocetine for cognitive impairment and dementia (Cochrane Review). Cochrane Database Systematic Review CD003119.Google Scholar
  56. Wake, G., Court, J., Pikering, A., Lewis, R., Wilkins, R., & Perry, E. (2000). CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. Journal of Ethnopharmacology, 69, 105–114.PubMedCrossRefGoogle Scholar
  57. Wheatley, D. (1999). Hypericum in seasonal affective disorder (SAD). Current Medical Research Opinion, 15, 33–7.CrossRefGoogle Scholar
  58. Xu, S. S., Gao, Z. X., & Weng, Z. (1995). Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer’s disease. Zhongguo Yao Li Xue Bao, 16, 391–395.PubMedGoogle Scholar
  59. Zhang, R. W., Tang, X. C., & Han, Y. Y. (1991). Drug evaluation of huperzine A in the treatment of senile memory disorders [in Chinese; English abstract]. Zhongguo Yao Li Xue Bao, 12, 250–252.PubMedGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  • Shahin Akhondzadeh
    • 1
  1. 1.FB Pharmacols, Psychiatric Research Center, Roozbeh HospitalTehran University of Medical SciencesSouth Kargar StreetIran

Personalised recommendations